von Eynatten, M., Gong, Y., Emser, A., & Woerle, H. (2013). Efficacy and safety of linagliptin in type 2 diabetes subjects at high risk for renal and cardiovascular disease: A pooled analysis of six phase III clinical trials. BioMed Central.
Styl Chicagovon Eynatten, Maximilian, Yan Gong, Angela Emser, a Hans-Juergen Woerle. Efficacy and Safety of Linagliptin in Type 2 Diabetes Subjects At High Risk for Renal and Cardiovascular Disease: A Pooled Analysis of Six Phase III Clinical Trials. BioMed Central, 2013.
Citace podle MLAvon Eynatten, Maximilian, Yan Gong, Angela Emser, a Hans-Juergen Woerle. Efficacy and Safety of Linagliptin in Type 2 Diabetes Subjects At High Risk for Renal and Cardiovascular Disease: A Pooled Analysis of Six Phase III Clinical Trials. BioMed Central, 2013.